Etoposide (VP-16) in the treatment of advanced adenocarcinoma of the pancreas Journal Article

  


Authors: Sternberg, C. N.; Magill, G. B.; Cheng, E. W.; Applewhite, A.; Sordillo, P. P.
Article Title: Etoposide (VP-16) in the treatment of advanced adenocarcinoma of the pancreas
Abstract: Twenty-six patients with advanced adenocarcinoma of the pancreas were treated with etoposide (VP-16), 100-180 mg/m2 i.v., days 1, 2, and 3, monthly. Twenty-five had bidimensionally measurable disease and one had evaluable disease only. This regimen and dosage schedule were well tolerated, with minimal toxicity including myelosuppression; a median WBC count nadir of 3,600 cells/mm3 (range 200-2,400); and a median platelet nadir of 215,000 cells/mm3 (range 15,000-405,000). However, no patients responded and only two had stable disease for 3.5 and 4 months, respectively. At this dosage and schedule, there is no role for VP-16 in the treatment of advanced pancreatic adenocarcinoma.
Keywords: clinical article; adenocarcinoma; etoposide; age; pancreas carcinoma; intravenous drug administration; human; male; female
Journal Title: American Journal of Clinical Oncology
Volume: 11
Issue: 2
ISSN: 0277-3732
Publisher: Lippincott Williams & Wilkins  
Date Published: 1988-04-01
Start Page: 172
End Page: 173
Language: English
DOI: 10.1097/00000421-198804000-00016
PUBMED: 3282425
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0023919645&doi=10.1097%2f00000421-198804000-00016&partnerID=40&md5=ea91f99339ecbb5b9d01060a0693bff9
Notes: Article -- Export Date: 6 August 2020 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Gordon B. Magill
    30 Magill
  2. Cora N. Sternberg
    36 Sternberg
  3. Peter P. Sordillo
    20 Sordillo
  4. Edgar Cheng
    16 Cheng
Related MSK Work